2Yokoyama H, Wada T, Furuichi K. Immunomodulation effects and clinical evidence of apheresis in renal diseases[J]. Ther Apher Dial, 2003, 7:497.
3Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE[J]. Arthritis Rheum, 1992,35:630 640.
4Hershko AY, Naparstek Y. Removal of pathogenic autoanti- bodies by immunoadsorption[J]. Ann N Y Acad Sci, 2005, 1051:635-646.
5Yokoyama H, Wada T, Furuichi K. Immunomodulation effects and clinical evidence of apheresis in renal diseases[J]. Ther Apher Dial, 2003,7:513-519.
6Griveas I, Sourgounis A, Visvardis G, et al. Immunoadsorption in lupus myocarditis[J]. Ther Apher Dial, 2004,8:281-285.
7Sugimoto K, Yamaji K, Yang KS, et al. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis[J]. Ther Apher Dial, 2006,10:187-192.
8Belak M, Borberg H, Jimenez C, et al. Therapeutical and Clinical Experience with Protein A Immunoadsouption Columns.Transfus Sci, 1994,15 : 419.
9Huestis D. W, Morrison F. S. Adverse Clinical Effects of immune Sorption With Staphylococcal Protein A Columns. Transfusion Medicine Reviews, 1996,10: 62.
10Fennelly DW, Norton L, Sznol M, et al. A phase Ⅱ trial of extraeorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer.Cancer, 1995,75: 2099.
